*Intravenous t-PA (150 mg/4 hr). §Intravenous t-PA (1.5 mg/kg/4 hr) and intravenous urokinase (0.5-2.0 million units).
Illntravenous t-PA (1.5 mg/kg/4 hr) and simultaneous fourth bolus heparin (10,000 units). ¶Intravenous urokinase (3 million units).
with the majority of improvement occurring within the first week after reperfusion.2-4 Thus, acute reperfusion therapy in humans has been built on the concept that left ventricular function would improve over time after thrombolysis and coronary reperfusion due to the salvage of "stunned" ischemic myocardium.
During the past several years, multiple clinical studies have been performed using aggressive coronary reperfusion strategies early in the course of acute myocardial infarction. The primary goals of these strategies, using intracoronary or intravenous thrombolytic agents with or without coronary angioplasty, have been to improve survival and salvage ischemic myocardium. Although the beneficial effects of these strategies on mortality have been established,5-7 their effect on left ventricular systolic function has been small and inconsistent, raising questions about whether other mechanisms may be responsible for the clinical benefit of thrombolytic therapy.8-14 One of the primary end points of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) studies was quantitative measurement of the change in regional and global left ventricular systolic function occurring during the first week after reperfusion therapy for acute myocardial infarction.
The purpose of this study was twofold. First, we sought to determine the changes that occur during the first week in global left ventricular ejection fraction and regional left ventricular wall motion in these studies involving thrombolysis and angioplasty therapy for acute myocardial infarction. Second, we sought to define the clinical, acute angiographic and treatment variables predictive of 7-day improvement in left ventricular ejection fraction and infarct zone regional wall motion in patients treated with these aggressive coronary reperfusion strategies. Methods
Patient Population
Of 805 patients prospectively enrolled in the TAMI trials (TAMI I, II, and III and urokinase studies), 542 had paired ventriculographic data (acutely and at 7 days), and they form the basis of this study. The details of the study designs have been described previously. '5-'8 Briefly, patients presenting within 6 hours of symptom onset of acute myocardial infarction were eligible. ECG ST frame. In both models, a set of 24 preselected predictors were examined (Table 3) .
The same process of model development was used for each of the two outcomes. This process involved a unique stepwise approach that allowed for model development in a clinically relevant fashion. First, clinical variables available to the physician at patient presentation were studied. With a backward selection technique, a subset of significant baseline clinical variables was derived (p<0.1). After adjusting for these clinical characteristics, a backward selection technique again was used to determine the significant acute angiographic variables. Finally, the treatment end point variables were added to the significant clinical and angiographic factors, and the backward selection technique again was used, resulting in a combined clinical, angiographic and treatment end point model.
To provide internal validation, the technique of bootstrapping was used.22 A random sample of two thirds of the population was drawn with replacement from the original sample. Backward elimination with linear regression modeling then was used on the "bootstrapped" sample. This step was repeated 40 times for each model, and the number of times each variable reached statistical significance (p<0.1) was calculated. An arbitrary threshold for replication was set at 75% (or 30 of 40 model validations).
Subgroup analysis also was performed comparing the left ventricular function of patients with successful acute reperfusion and no coronary reocclusion to the subgroup with unsuccessful acute reperfusion or infarctrelated artery reocclusion. Analysis of adjuvant coronary revascularization treatments on left ventricular function also was performed. The ventricular function of patients undergoing emergency angioplasty or coronary artery bypass grafting before the 7-day repeat catheterization was compared with the ventricular function of patients without these interventions. The angioplasty subgroup contained patients undergoing acute rescue angioplasty or emergency angioplasty for recurrent ischemia.
Results

Acute and 1-Week Ventricular Function
The mean left ventricular ejection fraction was 51.2±+ 11.1% during the acute study and was 51.9+11.0% at the 7-day study (p=0.19). Although no overall change in ejection fraction was demonstrated, a significant amount of interpatient variability was seen ( Figure 1 ). More than 25% of patients had an improvement of more than 5%, and more than 25% had a deterioration of ejection fraction of more than 5%. (Table 4) . Among the clinical variables, resolution of chest pain before acute catheterization again was related to improvement in infarct zone regional wall motion at 7 days. Unlike the global function analysis, history of hypertension was not associated with infarct zone regional improvement (p=0.70). In addition, inferior infarction was marginally related to improvement in infarct zone regional wall motion. Like the global function analysis, no relation was found between the duration of symptoms before administration of thrombolytic therapy and improvement in regional infarct zone function (p=0.597, Figure 3) .
When the angiographic and treatment variables were added into the analysis, acutely depressed infarct zone regional wall motion was the strongest predictor of subsequent improvement. This again was true when patients with prior infarctions were excluded from the analysis. Impaired regional wall motion in the noninfarct zone at the acute study also was associated with greater subsequent improvement in the infarct zone. In contrast to the findings for global left ventricular function, the absence of TIMI grade 0 flow rather than the presence of TIMI grade 3 flow as observed for global function was a more powerful predictor of improvement in infarct zone regional wall motion. Finally, emergency bU r 
Subgroup Analysis
Patients with acute reperfusion and sustained patency. Patients with successful, acute reperfusion at 90 minutes and sustained infarct-related artery patency at 7 days demonstrated better infarct zone regional function acutely and greater 7-day improvement in ejection fraction and infarct zone regional function compared with patients with unsuccessful acute reperfusion or infarct-related artery reocclusion ( Table 5 ). The trend toward greater acute ejection fraction in patients with successful sustained reperfusion did not reach statistical significance (p=0.14). Modest 7-day improvement in ejection fraction (1.4+9.5%) occurred in patients with successful reperfusion and sustained patency compared with a modest decrease in ejection fraction in patients with unsuccessful acute reperfusion or coronary reocclusion. Infarct zone regional function demonstrated less hypokinesis acutely as well as greater 7-day improvement in patients with successful, sustained reperfusion. Noninfarct zone regional function was not different in patients with successful, sustained reperfusion, and the 7-day change in noninfarct zone function was similar to that of patients with unsuccessful reperfusion or reocclusion.
Adjuvant revascularization treatments: angioplasty or bypass grafting. Patients who underwent coronary bypass grafting had lower ejection fractions at the acute study and reduced noninfarct zone regional function compared with patients who underwent angioplasty or who underwent neither angioplasty nor bypass grafting (Table 6 ). Patients undergoing angioplasty or bypass surgery had more severe hypokinesis in the infarct zone at the acute study than patients undergoing neither treatment. Patients undergoing bypass grafting demonstrated 7-day improvement in ejection fraction (3.6±10.3%) compared with no change in ejection fraction in the angioplasty and neither-therapy groups. The magnitude of the infarct zone regional wall motion improvement also was greater in the bypass subgroup. In the bypass subgroup, noninfarct zone regional function improved at 7 days compared with slight regression of noninfarct zone function in the other two subgroups.
Discussion
The present study, which describes the largest population of patients with serial acute and follow-up angiographic evaluation after thrombolytic therapy, demon- 
Comparison With Prior Studies
The lack of sizeable change in global function is consistent with previous reports. The TIMI I study group has produced the largest previous report with serial angiography, and the change over the duration of Allp<O.O5 (for bypass surgery versus angioplasty or neither) except 7-day noninfarct zone regional wall motion. 
Multivariable Analysis
Although no overall change in left ventricular function was observed before discharge, the lack of overall change resulted from substantial improvement in some patients and substantial deterioration in others. Regardless of whether improvement in global or regional function was the end point, the degree of acute impairment was the factor most closely associated with improvement in function; those patients with the worst function acutely were most likely to improve. This also held true when only patients with first myocardial infarctions were analyzed. Although this finding may be related in part to the statistical phenomenon of regression to the mean,30 it also suggests that patients with the greatest extent of jeopardized myocardium benefit the most from coronary reperfusion. Our 
Time to Treatment and Recovery of Function
Perhaps the most striking finding in this study is the lack of relation between time to treatment and subsequent improvement in left ventricular function. This finding exists despite the large number of patients and the careful measurement of both global and regional ventricular function in this study. Marzoll and colleagues also found no effect of time to treatment, whereas the TIMI investigators reported a weak relation.1931 This finding again suggests that variables related to subsequent improvement in left ventricular systolic function after coronary reperfusion in humans may be different and more complex than predicted by the canine models. One factor that was not measured in our study that is important in both the canine model and clinical studies is coronary collateral blood flow.37 Collateral flow to the distal bed of the infarct vessel may preserve some jeopardized myocardium, which may recover after thrombolysis and anterograde coronary reperfusion. In addition, infarct vessel patency and flow during acute myocardial infarction constitute a dynamic process, as demonstrated by the frequent occurrence of multiple changes in the level of ST segment elevation, which may affect the severity of myocardial ischemia and infarction.38 Despite these caveats, the consistency of these findings in a large number of patients evaluated in three separate studies makes it unlikely that the lack of relation between time to treatment and improvement in left ventricular function is artifact.
None of the studies reported to date, including ours, have had a large number of patients treated within the first hour of symptom onset. A recent meta-analysis demonstrated a direct relation between time to treatment and survival,39 results that are not reflected in the ventricular function data in this study. Patients treated within the first hour had a mortality reduction that was substantially greater than that predicted by the logistic regression model relating time to treatment to mortality. These results suggest that treatment within the first hour may result in markedly enhanced survival, perhaps due in part to preservation of left ventricular function, as well as other potential mechanisms such as improved healing and better electrophysiological properties.40 '41 Later treatment may result in quantitatively less survival enhancement because the ability to salvage sufficient myocardium to preserve systolic left ventricular function is lost.
Study Limitations
It must be emphasized that this study had no control or placebo group (i.e., all patients received intravenous thrombolytic therapy), and thus no conclusion can be drawn with respect to the effect of these coronary reperfusion strategies on left ventricular function compared with patients not treated with intravenous thrombolytics.
Although contrast left ventriculography is the gold standard for measuring left ventricular systolic function, some disadvantages are present. Left ventricular angiography, analyzed in the right anterior oblique view, can miss wall motion abnormalities in the posterolateral wall. This limitation is not major because in only 12% of the population was the circumflex the infarct-related artery.
In addition, whenever contrast ventriculography is used to measure left ventricular function, substantial dropout occurs, predominately in the sickest patients. The requirement for invasive 7-day restudy eliminated some of the highest-risk patients as reflected by the lower-risk characteristics and lower in-hospital mortality (Table 2) in patients with paired ventriculographic data.
The 7-day end point may not be adequate to define serial change in left ventricular function after coronary reperfusion. Res and colleagues,35 however, evaluating patients treated with intracoronary streptokinase, demonstrated improvement in ejection fraction 2 weeks after infarction but found no further change when ejection fraction was remeasured at 3 months. Our data reevaluating left ventricular function at 6 months and the TIMI data at 1 year did not show further change in left ventricular function compared with the 1-week, predischarge end point.42 '43 Implications We believe that this study has three major implications. Clinically, our findings reinforce the general principle that patients with the most myocardium in jeopardy benefit the most from reperfusion. No other criteria for selection of patients with more to gain from treatment could be identified. Successful reperfusion is associated with this improvement, so means of achieving reperfusion in a higher proportion of patients should be sought. Second, in comparative trials or analyses, the magnitude of differences in left ventricular function between treatments can be expected to be small. Finally, the large body of clinical data demonstrating the failure of reperfusion therapy to dramatically improve left ventricular function points to the need for a better understanding of the underlying pathophysiology following coronary reperfusion. Studies designed to compare infarct size and systolic function as well as basic investigation of the mechanism of irreversible injury could lead to new therapies to further enhance the benefit of coronary reperfusion.
